Patent ID: 9695237
Date: 2017-07-04
CPC Classifications: A61K,A61P,C07K,C12N,C12P,G01N

Claim:
1. A method for treating a disease associated with human folate receptor α (FOLR1)-positive cells in a subject in need thereof, comprising administrating a monoclonal antibody or an antibody fragment thereof into the subject, wherein the monoclonal antibody or the antibody fragment thereof competes with one antibody selected from the following (a)-(c) to specifically recognize human FOLR1 of SEQ ID NO: 1; wherein the monoclonal antibody or the antibody fragment thereof binds to an epitope identical to the epitope of the human FOLR1 of SEQ ID NO: 1 to which one antibody selected from the following (a)-(c) binds; wherein the monoclonal antibody or the antibody fragment thereof shows an anti-tumor activity: (a) an antibody in which complementarity determining regions (CDRs) 1-3 of heavy chain (H chain) of the antibody comprise the amino acid sequences of SEQ ID NOs: 30, 31, and 32, respectively and CDRs 1-3 of light chain (L chain) of the antibody comprise the amino acid sequences of SEQ ID NOs: 33, 34, and 35, respectively; (b) an antibody in which CDRs 1-3 of H chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 30, 31, and 32, respectively and CDRs 1-3 of L chain of the antibody comprise the amino acid sequences of SEQ ID NOs: 33, 34, and 35, respectively, and in which cysteine in the amino acid sequence of SEQ ID NO: 32 is substituted with threonine, methionine, isoleucine, valine, phenylalanine, or glutamine; and (c) an antibody in which H chain of the antibody comprises the amino acid sequence of SEQ ID NO: 98, and L chain of the antibody comprises the amino acid sequence of SEQ ID NO: 94; and wherein the disease associated with human FOLR1-positive cells is ovarian cancer.